Guo Jianming, Zheng Bin, Chen Tingting, Guo Shuyan, Liu Maobai, Dong Siping
Department of Pharmacy, Sanming Second Hospital, Sanming, Fujian Province, China.
Department of Pharmacy, Fujian Medical University Union Hospital, Fujian, 350000, People's Republic of China.
BMC Public Health. 2024 Dec 18;24(1):3458. doi: 10.1186/s12889-024-21013-7.
To prioritize the introducing of new vaccines into China's National Immunization Program (NIP) among 10 candidate vaccines across four classes.
We developed a vaccine value framework using Multi-Criteria Decision Analysis (MCDA) to simulate the introduction of new vaccines into NIP, covering 21 criteria encompassing six dimensions: safety, effectiveness, economy, innovation, accessibility, and appropriateness. Two decision scenarios were considered: Scenario One prioritized the four classes of vaccines, while Scenario Two identified specific vaccines within each class.
In the vaccine value framework, safety received the highest weight, while innovation received the lowest. The Human Papillomavirus (HPV) vaccine was identified as a top priority for inclusion in NIP, followed by Pneumococcal Conjugate Vaccine (PCV), Haemophilus Influenzae Type B (HIB), and Rotavirus (RV) vaccines. The specific types are domestic bivalent HPV vaccine, imported 13-valent PCV vaccine, domestic HIB vaccine, and domestic RV vaccine. The results of the one-way and probabilistic sensitivity analysis demonstrated robustness.
This study provides a transparent, comprehensive, and quantifiable vaccine value framework to aid decision-making for introducing new vaccines into China's NIP. According to the MCDA results, HPV should be considered the top vaccine candidate for the NIP.
在四类共10种候选疫苗中，确定将新疫苗纳入中国国家免疫规划（NIP）的优先顺序。
我们使用多标准决策分析（MCDA）建立了一个疫苗价值框架，以模拟新疫苗纳入国家免疫规划的情况，涵盖21项标准，涉及六个维度：安全性、有效性、经济性、创新性、可及性和适宜性。考虑了两种决策情景：情景一按疫苗类别确定优先顺序，情景二则在每类疫苗中确定具体疫苗。
在疫苗价值框架中，安全性权重最高，创新性权重最低。人乳头瘤病毒（HPV）疫苗被确定为纳入国家免疫规划的首要优先疫苗，其次是肺炎球菌结合疫苗（PCV）、b型流感嗜血杆菌（HIB）疫苗和轮状病毒（RV）疫苗。具体类型为国产二价HPV疫苗、进口13价PCV疫苗、国产HIB疫苗和国产RV疫苗。单因素和概率敏感性分析结果显示具有稳健性。
本研究提供了一个透明、全面且可量化的疫苗价值框架，以协助中国国家免疫规划引入新疫苗的决策。根据多标准决策分析结果，HPV应被视为国家免疫规划的首要候选疫苗。
